| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6000610 | Thrombosis Research | 2015 | 7 Pages |
â¢Almost 3% of Danish lymphoma patients had a VTE within one year post-diagnosis.â¢VTE incidence was elevated in patients diagnosed with aggressive lymphoma subtypes.â¢Central venous catheter use was strongly associated with short-term VTE risk.
BackgroundValid estimation of the incidence and risk factors for venous thromboembolism (VTE) among lymphoma patients has been limited by small studies focused on selected lymphoma subtypes and failure to account for death as a competing risk. Using a nationwide cohort of Danish lymphoma patients diagnosed from 2000 to 2010, we examined the incidence and risk factors for VTE and evaluated the transient impact of cancer treatments on VTE risk.MethodsMedical databases contained cancer, comorbidity, treatment, and VTE information. We computed VTE incidence rates (IRs) per 1000Â person-years and 1- and 2-year incidence accounting for competing risks. Using Cox proportional hazards models, we identified factors associated with VTE risk. In a nested self-controlled design, we evaluated the transient effect of chemotherapy, radiation, central venous catheter use and rituximab on VTE risk using logistic regression models and adjusted odds ratios (aORs).ResultsVTE IRs were >Â 40/1000Â person-years within 180Â days post-diagnosis, decreasing to 8/1000Â person-years in year two. VTE risk was 2.9% and 3.5% at 1 and 2Â years, respectively. Lymphoma subtype, central nervous system involvement, and elevated lactate dehydrogenase were associated with VTE risk. Central venous catheter use increased the transient odds of VTE (aORÂ =Â 6.7 (1.2, 28.1)).ConclusionsWe report a lower VTE incidence among lymphoma patients compared with prior studies. Lymphoma aggressiveness was the main driver of baseline VTE risk, whereas central venous catheter use increased transient risks. These accurate estimates may improve the identification of lymphoma subgroups at highest VTE risk, for whom future targeted prevention interventions may be beneficial.
